Literature DB >> 28323104

Cytotoxicity and genotoxicity of lipid nanocapsules.

Gaël Le Roux1, Hélène Moche2, Alejandro Nieto3, Jean-Pierre Benoit3, Fabrice Nesslany2, Frédéric Lagarce3.   

Abstract

Lipid nanocapsules (LNCs) offer a promising method for the entrapment and nanovectorisation of lipophilic molecules. This new type of nanocarrier, formulated according to a solvent-free process and using only regulatory-approved components, exhibits many prerequisites for being well tolerated. Although toxicological reference values have already been obtained in mice, interaction of LNCs at the cell level needs to be elucidated. LNCs, measuring from 27.0±0.1nm (25nm LNCs) and 112.1±1.8nm (100nm LNCs) and with a zeta potential between -38.7±1.2mV and +9.18±0.4mV, were obtained by a phase inversion process followed by post-insertion of carboxy- or amino-DSPE-PEG. Trypan blue, MTS and neutral red uptake (NRU) assays were performed to evaluate the cytotoxicity of LNCs on mouse macrophage-like cells RAW264.7 after 24h of exposure. The determination of 50% lethal concentration (LC50) showed a size effect of LNCs on toxicity profiles: LC50 ranged from 1.036mg/L (MTS) and 0.477mg/mL (NRU) for 25nm LNCs, to 4.42mg/mL (MTS) and 2.18mg/mL (NRU) for 100nm LNCs. Surfactant Solutol® HS15 has been shown to be the only constituent to exhibit cytotoxicity; its LC50 reached 0.427mg/mL. Moreover, LNCs were not more toxic than their components in simple mixtures. At sublethal concentration, 100nm LNCs only were able to induce a significant production of nitric oxide (NO) by RAW264.7 cells, as assessed by the Griess reaction. Again, surfactant was the only component responsible for an increased NO release (1.8±0.2-fold). Genotoxicity assays revealed no DNA damage on human lymphocytes in both the in vitro Comet and micronucleus assays using 4-hour and 24-hour treatments, respectively.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Captex® 8000; Cytotoxicity; Genotoxicity; Hill modelisation; Lipid nanocarriers; Lipoid® S75-3; MTS assay; Micronucleus test; Nanotoxicology; Neutral red uptake assay; Nitric oxide; Single-cell gel electrophoresis; Solutol® HS15; Trypan blue assay

Mesh:

Substances:

Year:  2017        PMID: 28323104     DOI: 10.1016/j.tiv.2017.03.007

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  9 in total

1.  A modular approach toward producing nanotherapeutics targeting the innate immune system.

Authors:  Mandy M T van Leent; Anu E Meerwaldt; Alexandre Berchouchi; Yohana C Toner; Marianne E Burnett; Emma D Klein; Anna Vera D Verschuur; Sheqouia A Nauta; Jazz Munitz; Geoffrey Prévot; Esther M van Leeuwen; Farideh Ordikhani; Vera P Mourits; Claudia Calcagno; Philip M Robson; George Soultanidis; Thomas Reiner; Rick R M Joosten; Heiner Friedrich; Joren C Madsen; Ewelina Kluza; Roy van der Meel; Leo A B Joosten; Mihai G Netea; Jordi Ochando; Zahi A Fayad; Carlos Pérez-Medina; Willem J M Mulder; Abraham J P Teunissen
Journal:  Sci Adv       Date:  2021-03-05       Impact factor: 14.957

2.  Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia.

Authors:  Thomas Briot; Emilie Roger; Nolwenn Lautram; Alexis Verger; Anne Clavreul; Frederic Lagarce
Journal:  Int J Nanomedicine       Date:  2017-11-23

3.  Praziquantel-lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting.

Authors:  Rokaya O Amara; Alyaa A Ramadan; Riham M El-Moslemany; Maha M Eissa; Mervat Z El-Azzouni; Labiba K El-Khordagui
Journal:  Int J Nanomedicine       Date:  2018-08-06

4.  Particle Engineering of Innovative Nanoemulsion Designs to Modify the Accumulation in Female Sex Organs by Particle Size and Surface Charge.

Authors:  Eike Folker Busmann; Henrike Lucas
Journal:  Pharmaceutics       Date:  2022-01-27       Impact factor: 6.321

5.  Identification of natural cytochalasins as leads for neglected tropical diseases drug discovery.

Authors:  Marilia Valli; Julia Medeiros Souza; Rafael Consolin Chelucci; Carolina Rabal Biasetto; Angela Regina Araujo; Vanderlan da Silva Bolzani; Adriano Defini Andricopulo
Journal:  PLoS One       Date:  2022-10-03       Impact factor: 3.752

6.  Formulation and In Vitro Characterization of PLGA/PLGA-PEG Nanoparticles Loaded with Murine Granulocyte-Macrophage Colony-Stimulating Factor.

Authors:  Nicole E Mihalik; Sijin Wen; Benoit Driesschaert; Timothy D Eubank
Journal:  AAPS PharmSciTech       Date:  2021-06-24       Impact factor: 4.026

7.  Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma.

Authors:  Anne Clavreul; Emilie Roger; Milad Pourbaghi-Masouleh; Laurent Lemaire; Clément Tétaud; Philippe Menei
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

8.  Biological response and cytotoxicity induced by lipid nanocapsules.

Authors:  Marzena Szwed; Maria Lyngaas Torgersen; Remya Valsala Kumari; Sunil Kumar Yadava; Sascha Pust; Tore Geir Iversen; Tore Skotland; Jyotsnendu Giri; Kirsten Sandvig
Journal:  J Nanobiotechnology       Date:  2020-01-06       Impact factor: 10.435

9.  Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules.

Authors:  Laura Pinton; Sara Magri; Elena Masetto; Marina Vettore; Ilaria Schibuola; Vincenzo Ingangi; Ilaria Marigo; Kevin Matha; Jean-Pierre Benoit; Alessandro Della Puppa; Vincenzo Bronte; Giovanna Lollo; Susanna Mandruzzato
Journal:  J Nanobiotechnology       Date:  2020-02-17       Impact factor: 10.435

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.